


1 Accepted version published at:



Review > Int Urogynecol J. 2022 Feb 4. doi: 10.1007/s00192-022-05088-7. Online ahead of print.

The effectiveness of different electrical nerve stimulation protocols for treating adults with non-neurogenic overactive bladder: a systematic review and meta-analysis

Kamilla Zomkowski¹, Ingridy Kammers², Bruna Baungarten Huguen Back²,
Géssica Maria Moreira², Anelise Souza², Cinara Sacomori^{3,4}, Fabiana Flores Sperandio²

Affiliations + expand

PMID: 35119495 DOI: 10.1007/s00192-022-05088-7

2

3 **The effectiveness of different electrical nerve stimulation protocols for treating adults**
4 **with non-neurogenic overactive bladder: a systematic review and meta-analysis**

5

6 Kamilla Zomkowski¹, Ingridy Kammers², Bruna Baungarten Huguen Back², Géssica Maria
7 Moreira², Anelise Souza², Cinara Sacomori^{3,4*}, Fabiana Flores Sperandio²

8

9 1 Universidade do Sul de Santa Catarina, Palhoça, SC, Brazil.

10 2 Universidade do Estado de Santa Catarina, Physical Therapy Department, Florianópolis,
11 SC, Brazil.

12 3 Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Escuela de
13 Kinesiología, Santiago de Chile, Chile

14 4 Universidad Bernardo O'Higgins, Santiago de Chile, Chile.

15

16 ***Corresponding author:** Cinara Sacomori. Facultad de Medicina Clínica Alemana
17 Universidad del Desarrollo, Santiago de Chile. E-mail: csacomori@yahoo.com.br, Phone:
18 +56-2-23279416.

19

20 **Conflict of Interest for all authors** - None

21 **Funding:** None

22 **Acknowledgements:** The authors would like to thank Professor Marcos de Noronha from
23 LaTrobe University, for supporting the meta-analysis process.

24 **Author contributions:** **K. Zomkowski:** Protocol/project development; Data collection or
25 management; Formal analysis; Methodology; Project administration; Manuscript
26 writing/editing. **I. Kammers:** Data collection or management; Formal analysis; Methodology;
27 Manuscript writing/editing. **B. B. Huguen Back:** Data collection or management; Formal
28 analysis; Methodology; Manuscript writing/editing. **G. M. Moreira:** Validation;
29 Visualization; Manuscript writing/editing. **A. Sonza:** Protocol/project development;
30 Validation; Manuscript writing/editing. **C. Sacomori:** Protocol/project development;
31 Methodology; Validation; Manuscript writing/editing. **F. F. Sperandio:** Protocol/project
32 development; Methodology; Validation; Visualization; Manuscript writing/editing.

33

34 Abstract word count: 250

35 Manuscript Word Count: 2768

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 **The effectiveness of different electrical nerve stimulation protocols for treating adults**
51 **with non-neurogenic overactive bladder: a systematic review and meta-analysis**

52

53

54 **Abstract**

55 **Introduction and Hypothesis:** Electrical nerve stimulation is a widely used treatment for

56 overactive bladder but there is no consensus regarding the best placement of electrodes or

57 protocols. We hypothesized that some non-implanted neurostimulation protocols would be

58 more effective compared to others for treating urinary symptoms and improving quality of life

59 among adults diagnosed with non-neurogenic overactive bladder. **Methods:** A systematic

60 review and meta-analyses of randomized clinical trials were performed in five electronic

61 databases: Pubmed/Medline, Lilacs, CINAHL, Web of Science, and PEDro. The main

62 outcome was urinary symptoms - frequency, nocturia, urgency - and the secondary outcome
63 quality of life. Some protocols characteristics were extracted, as frequency, pulse width,
64 intensity, intervention time, and electrode placement. **Results:** Nine randomized controlled
65 trials were included. Tibial neurostimulation showed better results than sacral
66 neurostimulation for urge-incontinence (mean difference=1.25 episodes, 95% CI, 0.12-2.38,
67 n=73). On the pooled analysis, the different neurostimulation protocols – intravaginal,
68 percutaneous tibial and transcutaneous tibial nerve stimulation – demonstrated similar results
69 for urinary frequency, nocturia, and urgency, as well as for quality of life. In general, effect
70 sizes from meta-analyses were low to moderate. The best reported parameters for
71 percutaneous tibial nerve stimulation were 20Hz frequency and 200µs width, once a week.
72 **Conclusions:** There was evidence that tibial neurostimulation is more effective than sacral
73 neurostimulation for urge-incontinence symptoms among patients with non-neurogenic
74 overactive bladder. Overall, there was no superiority of an electrical nerve stimulation
75 electrodes placement and protocol over others considering urinary symptoms and quality of
76 life. Further studies with three-arm trials are necessary. **PROSPERO:** CRD4201810071.
77 **Key words:** Urinary Incontinence, Urge; Urinary Bladder, Overactive; transcutaneous
78 electrical nerve stimulation; quality of life.

79

80 **Brief summary**

81 This was a systematic review and meta-analysis of neuromodulation protocols to treat non-
82 neurogenic overactive bladder symptoms. Tibial neurostimulation showed to be more
83 effective than sacral neurostimulation for urge-incontinence symptoms.

84

85 **Abbreviations**

86 OAB - Overactive bladder

87 QoL – Quality of life

88 ICIQ-OAB - International Consultation on Incontinence Questionnaire Overactive Bladder

89 I-QOL - Incontinence Quality of Life Instrument

90 OAB-q SF - Overactive Bladder Questionnaire Short Form

91 MD – mean difference

92

93

94

95

96 **Introduction**

97 Overactive bladder (OAB), according to the International Continence Society, is a complex
98 dysfunction encompassing symptoms of urgency, augmented urinary frequency, and nocturia,
99 which may also be associated with urinary incontinence [1]. Approximately two-thirds of
100 women and one-third of men develop urinary incontinence associated with OAB, affecting
101 quality of life (QoL) [2,3]. The first line treatment for OAB is cognitive behavioural therapy
102 and the second line treatment is the pharmacological management with anti-muscarinic or
103 agonist of β 3-adrenoreceptor drugs [3], which lead to various negative side effects in several
104 systems such as the gastrointestinal, cardiac, neurological, urogynecological, and nasopharynx
105 [4,5] systems. Hence, due to their low tolerance and low adherence rates, the use of these
106 drugs is limited among older individuals.

107 Current practice recommends the use of neurostimulation as non-pharmacological and
108 alternative treatment option for OAB particularly whether conventional treatment fails or if
109 the medications are not tolerated [3,6]. The detrusor overactivity can be suppressed by two
110 different mechanisms, the first occurs by direct inhibition of bladder preganglionic neurons,
111 and the second by inhibition of interneuronal transmission in the afferent limb micturition
112 reflex [7]. Neurostimulation aims to inhibit the reflex activity of the detrusor muscle by
113 stimulating somatic afferent pathways capable to block the processing of visceral afferent
114 signals, therefore, electric stimulation of the nerve or dermatome blocks the afferent inputs
115 from bladder. The tibial nerve (L4-S3) divides the sacral roots with somatic afferent pudendal
116 nerve (S2-S4), providing inhibition of sensory processing spinal cord [3,5–8]. The mechanism
117 explaining why neurostimulation is effective for treating OAB is not fully understood.
118 Despite voiding control being mostly voluntary, various somatic and visceral afferent nerve
119 stimulations, including electrical stimulation, may awaken the primitive mechanism of
120 inhibitory modulation of the micturition reflex in the spinal cord [7]. Electrical superficial
121 electrodes, vaginal or anal probes stimulate motor efferent fibres of the pudendal nerve,
122 causing pelvic floor muscle contractions that inhibit detrusor contractions by activating A3
123 Mahoney reflex, which postpone the micturition desire [9].

124 Neurostimulation protocols for OAB can be transcutaneous, covering three possible
125 placement regions for the surface electrodes: over the sacrum in the region of the sacral nerve
126 roots [8], over the tibial nerve at the ankle [3,8], or intra-vaginal. It can also be percutaneous,
127 with needle electrodes inserted near the tibial nerve [8,10]. Preliminary evidence shows
128 neurostimulation to be a safe and cost-effective intervention for reducing urinary symptoms
129 and improving long-term QoL [3,6,11,12]. Studies comparing the use of neurostimulation to
130 placebo/sham treatment or with pharmacological treatment shows beneficial results for OAB
131 [3,5,6,8].

132 This notwithstanding, the findings are inconclusive regarding the most appropriate
133 neurostimulation protocol considering different parameter settings such as frequency, pulse
134 width, and intensity, highlighting the absence of intervention parameters consensus [6,10,11].
135 The nonexistence of standardized protocols might compromise the effectiveness of OAB
136 treatment. The guideline from the American Urological Association classifies the use of
137 peripheral tibial nerve stimulation for non-neurogenic OAB as a third-line treatment with an
138 evidence strength of grade C [3]. Also, the sacral implanted neuromodulation is
139 recommended as a third line treatment for patients with severe refractory OAB symptoms
140 with an evidence strength of grade C. This is an invasive treatment as an implantable device is
141 placed on iliac crest and the electrodes are directly connected into S3-S4 levels [3]. Thus, it is
142 not the focus of the present study.

143 In addition, systematic reviews [6,10,11] and a guideline [3] suggest forthcoming
144 studies with higher levels of evidence, aiming at standardization of neurostimulation protocols
145 for OAB to improve health outcomes [3,6,10,11]. Therefore, considering the great usability
146 and wide variability of neurostimulation protocols for non-neurogenic OAB treatment, the
147 aim of the present study was to analyse current literature on the effectiveness of different
148 neurostimulation protocols for treating urinary symptoms and improving quality of life among
149 adults diagnosed with non-neurogenic overactive bladder.

150

151 **Materials and Methods**

152

153 **Design**

154

155 This systematic review report is based on the PRISMA (Preferred Reporting Items for
156 Systematic Reviews and Meta-Analyses) guidelines [13] and was registered at the
157 International Prospective Register of Systematic Reviews - PROSPERO (CRD4201810071).

158

159 **Search strategy**

160

161 Systematic searches were performed in five databases on 19/04/2020:
162 Pubmed/Medline (via National Library of Medicine), Lilacs, CINAHL with full text
163 (EBSCO), Web of Science (Thomson Reuters Scientific), and PEDro. A further manual
164 search of the included references was also conducted. The full search strategy is available as
165 supplementary material.

166

167 **Inclusion Criteria**

168

169 The inclusion criteria were: (1) adults aged over 18 with a diagnosis of non-
170 neurogenic OAB; (2) randomized clinical trials or quasi-randomized clinical trials comparing
171 different protocols of neurostimulation (e.g., frequency, pulse width, intensity, intervention
172 time, and electrode placement); (3) related to the primary outcomes nocturia, urinary
173 frequency, urgency, and urge-incontinence; and the secondary outcome QoL. The included
174 studies were articles published in English, Spanish, French, and Portuguese. Articles with
175 sacral neuromodulation implants were excluded.

176 **Data extraction and quality assessment**

177

178 After the database searches, titles were screened to identify duplicate publications
179 which were removed. KZ, IK, and BBHB screened titles to find potential studies for full

180 reading and, in sequence, the three authors extensively read the available articles to select
181 those that met the eligibility criteria. Any disagreements were resolved by consensus. The
182 extracted information included authorship, year of publication, sample characteristics (age
183 and clinical diagnosis), instruments, neurostimulation protocol, results, and study limitations.

184 The methodological quality of the included studies was assessed by the Risk of Bias
185 tool from the Cochrane Collaboration [14]. Studies were classified as good quality (low risk
186 in all items); fair quality (high risk of bias for one domain or two criteria unclear); poor
187 quality (two or more criteria listed as a high or unclear risk of bias).

188

189 **Data analysis**

190

191 Data were analysed as continuous variables and presented as standardized mean
192 differences (SMD) and 95% confidence intervals to pool primary and secondary outcomes.
193 Meta-analyses were performed on Review Manager (RevMan®) [Computer program],
194 Version 5.3 (Copenhagen, The Cochrane Collaboration, 2014), comparing the different
195 neurostimulation protocols which were visually displayed in the forest plot. The data
196 heterogeneity was assessed through I^2 statistics. If significant heterogeneity was identified
197 ($I^2 > 50\%$), studies were pooled for meta-analysis using a random-effects model; if not a fixed-
198 effects model was chosen. The value of effect sizes was interpreted as follows, in accordance
199 with Cohen: effect size < 0.5 = small; effect size $0.5-0.8$ = moderate; effect size > 0.8 = large¹⁵.

200

201 **Results**

202

203 **Flow of studies through the review**

204

205 The first literature search of electronic bibliographic databases retrieved 3024 titles:
206 757 were from Lilacs, 41 from PEDro, 388 from Web of Science, 1070 from
207 Pubmed/Medline, and 768 from CINAHL. After removing duplicates, 1944 studies were
208 screened by titles and abstracts and 29 were considered potentially relevant. After full reading
209 of the available articles, nine studies met the inclusion criteria; details from the search are
210 available in supplementary file 1. Four studies were added and, after manual screening of the
211 references from included studies, no further studies were selected. Thus, nine studies were
212 analysed in this systematic review. The flowchart of the selected studies is available in Figure
213 1.

214
215 [Insert Figure 1 here]

216 217 **Characteristics of the included studies**

218
219 Among the included studies, the countries that published the articles were: Brazil [16–
220 19] India [20], Turkey [21], Italy [22], the United Kingdom [23], and Spain [24]. The
221 publication years ranged from 2011 to 2020, demonstrating ongoing interest in this treatment
222 option. The studies included from 15 to 101 subjects (464 subjects in total). The average age
223 of participants in all studies ranged from 41.8 to 69.57 years. In addition to the diagnosis of
224 OAB, only one study included subjects with mixed urinary incontinence [16], which means a
225 diagnosis of non-neurogenic OAB associated with stress-related urinary incontinence. Seven
226 studies had a two-arm design [16,17,19, 21–24], while two had a three-arm design [18,20].

227 228 **Methodologic quality of the included studies**

229

230 Five studies were considered of poor quality [16,19,21,22,24] and four of fair quality
231 [17,18,20,23] (Figure 6). Approximately 44.4% of the studies presented an unclear risk of
232 selection bias, 66.6% an unclear risk for performance bias, 55.5% an unclear risk for detection
233 bias, and 77.7% an unclear risk for reporting bias.

234

235 **Effect of intervention**

236

237 There was great variability in the adopted neurostimulation parameter settings, such as
238 frequency, pulse width, intensity, application time, and electrode placement. Neurostimulation
239 of the tibial nerve (transcutaneous or percutaneous) was investigated in all included studies.
240 Percutaneous stimulation was applied in four studies [21-24] intra-vaginal transcutaneous
241 neurostimulation was performed in three [16,21,22], and stimulation in the sacrum region in
242 three [17,19,20]. The treatment protocols are available in table 1.

243

244 [Insert Table 1 here]

245

246 **Assessment Instruments**

247

248 Several instruments were used to evaluate the outcomes of the studies (Table 1). The
249 most used instruments were a voiding diary [16,17,19,21–24] and the International
250 Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) [17,18].
251 Regarding QoL, the most common instruments were the Incontinence Quality of Life
252 Instrument (I-QOL) [16,24], the Overactive Bladder Questionnaire Short Form (OAB-q SF)
253 [22,23], and the International Consultation on Incontinence Questionnaire Overactive Bladder

254 (ICIQ-OAB) [17–19]. Other instruments were used to identify the symptoms of urgency in
255 subjects, and the perception of improvement (Table 2).

256

257 **Intravaginal versus tibial neurostimulation**

258

259 Three studies compared intra-vaginal with tibial neurostimulation regarding urinary
260 frequency and nocturia (Figure 2A and 2B). Results for urgency and urge-incontinence could
261 not be pooled as quality assessment showed high risk of reporting, detection, and performance
262 bias [21,22], and one study reported unclear risk also for selection bias [17].

263

264 [insert figure 2 here]

265

266 On pooled results, no significant differences were found between intravaginal and
267 tibial neurostimulation for urinary frequency [Mean difference (MD) -0.24 times a day,
268 95%CI -1.45 to 0.96, n=69] and for nocturia (MD 0.07 times that urinate during sleeping
269 hours, 95% CI -0.22 to 0.37, n=69).

270

271 **Transcutaneous versus percutaneous tibial neurostimulation**

272

273 Two studies compared transcutaneous with percutaneous tibial neurostimulation. One
274 of them reported no differences regarding urinary frequency, nocturia, urgency, urge-
275 incontinence, and voided volume [24]. On pooled results, no significant differences were
276 found for urgency (MD= 0.70 episodes per day, 95%CI -1.06 to 2.45, n=92), urinary
277 frequency found (MD= -0.66 times a day, 95%CI -1.50 to 0.17, n=92), and urge-incontinence
278 (MD= 0.25 episodes per day, 95%CI – 0.50 to 0.99, n=92) - Figures 3A and 3B. Considering

279 the risk of bias, both studies showed a fair quality. Unclear bias risk was reported for
280 performance [23,24], detection [24] and reporting [23,24].

281 [insert figure 3 here]

282

283 **Sacral versus tibial neurostimulation**

284 Three studies compared the neurostimulation of the sacral nerve with the posterior
285 tibial nerve. One of them performed a three-arm trial, although it could not be pooled on
286 meta-analysis because it provided only the full score of OABSS and did not report specific
287 symptoms [20]. This study, which had a fair methodological quality and reported an unclear
288 risk for selection bias, found that simultaneous stimulation of sacral and tibial nerve was more
289 effective in relieving the symptoms of OAB when compared to sacral or tibial nerve
290 stimulation alone [20]. The other two studies were pooled (figure 4 A and 4B) [17,19].

291 Regarding the risk of bias, two were of fair quality and reported an unclear risk for selection
292 bias [17,19], performance bias, detection bias [19], reporting bias [19,20], and other biases
293 [17].

294

295 [insert figure 4 here]

296

297 One low-risk of bias RCT [17] and one high-risk of bias RCT [19] assessed urge
298 incontinence after sacral or tibial nerve stimulation and found better results to tibial nerve
299 compared to sacral stimulation (MD 1.25, 95%CI 0.12 to 2.38, n=73). Regarding urinary
300 frequency (MD 0.03, 95%CI -1.26 to 1.32, n=73), no differences were found.

301

302 **Quality of life**

303

304 Patient QoL was reported in all included studies. Regarding the different protocol
305 effects on QoL, none of the pooled results showed difference to favour any of the protocols
306 (Figure 5). When analysing table 2 that compared intra-vaginal nerve stimulation with tibial
307 neurostimulation, one study demonstrated improvement of QoL on OAB-q SF 6 ($p=0.017$)
308 and OAB-q SF13 scores ($p=0.019$) after tibial neurostimulation [22]. Another study that
309 showed significant results regarding QoL compared sacral nerve stimulation with tibial
310 neurostimulation, and both UDI-6 ($p=0.048$) and IIQ-7 ($p=0.038$) scores were improved [20].

311

312 **Discussion**

313

314 This systematic review and meta-analyses aimed to analyse current literature on the
315 effectiveness of different neurostimulation protocols for treating urinary symptoms and
316 improving quality of life among adults diagnosed with non-neurogenic OAB. Our results
317 showed no difference between protocols for urinary frequency, nocturia and quality of life.
318 But there was evidence for supporting the use of posterior tibial neurostimulation for
319 improving urge incontinence compared to sacral superficial nerve stimulation. This result
320 could be explained as the tibial nerve is more superficial in relation to sacral nerve roots, the
321 transcutaneous electrodes placed on tibial posterior muscle awake the inhibitory primitive
322 reflex in the spinal cord, arousing the inhibitory reflex on detrusor and normalizing the
323 bladder functioning [7].

324 Tibial neurostimulation was performed in all the included studies at the present this
325 systematic review. The percutaneous modality was applied in four studies [21–24], while the
326 other studies used transcutaneous application [13–16,18–20]. No differences were found in
327 the between-group analysis regarding percutaneous or transcutaneous tibial neurostimulation
328 application [19,20]. These results are consistent with previous reviews, which highlighted the

329 effectiveness of tibial neurostimulation when compared to sham groups [6]. Similarly,
330 guidelines consider tibial neurostimulation the best treatment option for OAB in clinical
331 practice [3], as it presents analogous results to pharmacological treatment, without the
332 reported systemic side effects. In addition, previous authors reported that tibial
333 neurostimulation is a more comfortable, safer, and cost-effective treatment option [25].
334 Regarding urinary symptoms and QoL, tibial neurostimulation presented more positive effects
335 when compared to intra-vaginal application [18].

336 Three previous systematic reviews analysed the effects of neurostimulation protocols
337 for non-neurogenic OAB with sham/placebo groups but, unlike our study, did not compare
338 different neurostimulation protocols. A previous review involved findings with a moderate-to-
339 high risk of bias, showed that neurostimulation improved the non-neurogenic OAB in
340 children [26]. The second review found moderate quality evidence supporting the use of
341 percutaneous tibial neurostimulation; though, it included both trials and observational studies
342 [12]. The third review concluded that electrical stimulation appeared to be more effective than
343 no treatment and drug treatment for OAB [9]. The findings of our systematic review are
344 specific to non-neurogenic OAB in adults treated with neurostimulation and, in contrast to the
345 previous reviews, we focused on analysis of the most effective neurostimulation protocol.

346 Despite the lack of consensus regarding neurostimulation parameter settings, the data
347 presented herein are in accordance with the American Urology Association [29], which
348 suggests neurostimulation should be performed twice a week for 30 minutes, for 12 weeks
349 [3]. One trial with patients with neurogenic overactive bladder due to spinal cord injury also
350 suggests that transcutaneous tibial nerve stimulation improved urodynamic parameters,
351 generating similar results as those obtained with anticholinergics [30].

352 The results from this systematic review should be interpreted with caution, as most of
353 studies had flaws in their methodologies, especially the lack in blinding of participants and

354 personnel and selective reporting, since most of studies did not publish their protocols. There
355 was a wide range of different protocols among studies, hindering the comparison between
356 different protocols.

357 As with any study of this nature, there is a potential bias in study selection. Five
358 studies were not fully available on the internet and, despite our efforts to contact the authors
359 to request these studies, we did not succeed. Another limitation was the absence of a clear
360 description of the neurostimulation protocols proposed by the authors. The strengths were the
361 inclusion of many languages; searches in five databases; no filters added in the searches; and
362 the investigation of intervention programs with distinct neurostimulation parameter settings
363 and protocols. Moreover, all included studies used reliable and reproducible assessment
364 methods for urinary symptoms and QoL. All the included studies presented low dropout rates,
365 which minimized the bias for observed effects and, consequently, provided more accurate
366 data regarding the effectiveness of the proposed treatments [27].

367 Thus, given the absence of standardized intervention protocols, we strongly suggest
368 further studies with a more rigorous methodological plan, with major sample sizes and a
369 clearer description of electrical stimulation parameters, preferably trials with a three-arm
370 design are necessary to investigate the optimisation of electrical neurostimulation parameters
371 for treating non-neurogenic OAB and to avoid loop inconsistencies [28]. In addition, we
372 recommend forthcoming studies that assess the comfort of neurostimulation modalities.
373 Multimodal studies are welcome specially if further studies explore the benefits and
374 effectiveness of the combination of neurostimulation with behavioural therapy for OAB.

375 In conclusion, the present study shows evidence for the use of tibial posterior
376 neurostimulation within a frequency of 20 Hz and 200 μ s width once a week for treating urge-
377 incontinence in non-neurogenic OAB patients.

378

379

380

381

382

383

384

385

386

387

388

389 **Funding:** None.

390 **Conflict of Interest:** The authors declare that there is no conflict of interest

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409 **References**

410 1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary
411 tract function: report from the Standardisation Sub-committee of the International Continence
412 Society. *Am J Obstet Gynecol.* 2002;187(1):116-126. doi 10.1067/mob.2002.125704.

413 2. Soler R, Gomes CM, Averbek MA, Koyama M. The prevalence of lower urinary
414 tract symptoms (LUTS) in Brazil: Results from the epidemiology of LUTS (Brazil LUTS)
415 study. *Neurourol Urodyn.* 2018;37(4):1356-1364. doi:10.1002/nau.23446

416 3. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of
417 overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. *J Urol.*
418 2015;193(5):1572-1580. doi:10.1016/j.juro.2015.01.087

- 419 4. White N, Iglesia CB. Overactive Bladder. *Obstet Gynecol Clin North Am.*
420 2016;43(1):59-68. doi:10.1016/j.ogc.2015.10.002
- 421 5. Truzzi JC, Gomes CM, Bezerra CA, et al. Overactive bladder - 18 years - Part II. *Int*
422 *Braz J Urol.* 2016;42(2):199-214. doi: 10.1590/S1677-5538.IBJU.2015.0367.
- 423 6. Wibisono E, Rahardjo HE. Effectiveness of Short Term Percutaneous Tibial Nerve
424 Stimulation for Non-neurogenic Overactive Bladder Syndrome in Adults: A Meta-analysis.
425 *Acta Med Indones.* 2015;47(3):188-200.
- 426 7. Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works.
427 *Urol Clin North Am.* 2005;32(1):11-18. doi:10.1016/j.ucl.2004.09.004
- 428 8. NICE. Urinary incontinence in women: Urinary incontinence in women: management
429 management Clinical guideline. 2013:1-50.
- 430 9. Stewart F, Lf G, R ED, Mo G, Kapoor A, JI A. Electrical stimulation with non-
431 implanted electrodes for overactive bladder in adults (Review). *Cochrane Database Syst Rev.*
432 2016;(4):CD010098. doi:10.1002/14651858.CD010098.pub3.www.cochranelibrary.com
- 433 10. Jerez-Roig J, Souza DLB, Espelt A, Costa-Marín M, Belda-Molina AM. Pelvic Floor
434 Electrostimulation in Women With Urinary Incontinence and/or Overactive Bladder
435 Syndrome: A Systematic Review. *Actas Urológicas Españolas.* 2013;37(7):429-444.
436 doi:10.1016/j.acuro.2012.08.003
- 437 11. Booth J, Connelly L, Dickson S, Duncan F, Lawrence M. The effectiveness of
438 transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome:
439 A systematic review. *Neurourol Urodyn.* 2018;37(2):528-541. doi:10.1002/nau.23351

- 440 12. Wang, M., Jian, Z., Ma, Y., Jin, X., Li, H., & Wang, K. Percutaneous tibial nerve
441 stimulation for overactive bladder syndrome: a systematic review and meta-analysis. *Int*
442 *Urogynecol J.* 2020. doi 10.1007/s00192-020-04429-8.
- 443 13. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting
444 items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ.*
445 2009;339:b2535. doi: 10.1136/bmj.b2535.
- 446 14. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*
447 Version 5.1.0 [Updated March 2011]. The cochrane collaboration; 2011.
- 448 15. Cohen J. *Statistical power analysis for the behavioral sciences.* 2nd. New York,
449 Routledge, 1988.
- 450 16. de Menezes Franco M, de Oliveira Souza F, Cristine Lemes Mateus de Vasconcelos E,
451 et al. Evaluation of quality of life and loss urine of women with overactive bladder treated
452 with intravaginal or tibial nerve electro stimulation. *Fisioter e Pesqui .* 2011;18(2):145-150.
453 doi 10.1590/S1809-29502011000200008.
- 454 17. Jacomo RH, Alves AT, Lucio A, Garcia PA, Lorena DCR, de Sousa JB.
455 Transcutaneous tibial nerve stimulation versus parasacral stimulation in the treatment of
456 overactive bladder in elderly people: a triple-blinded randomized controlled trial. *Clinics (Sao*
457 *Paulo).* 2020;75:e1477. doi:10.6061/clinics/2020/e1477.
- 458 18. Teixeira Alve A, Azevedo Garcia P, Henriques Jácomo R, et al. Effectiveness of
459 transcutaneous tibial nerve stimulation at two different thresholds for overactive bladder
460 symptoms in older women: a randomized controlled clinical trial. *Maturitas.* 2020;135:40-46.
461 doi:10.1016/j.maturitas.2020.02.008.

- 462 19. Santos BR dos, Gomes JL, Pompermayer RCL, Abreu GKP. Os benefícios da
463 eletroestimulação transcutânea via nervo tibial posterior e parassacral no tratamento de bexiga
464 hiperativa. *Fisioter Bras.* 2019;20(2):239-248. doi 10.33233/fb.v20i2.2420.
- 465 20. Surbala L, Ratan Khuman P, Mital V, Devanshi B. Neuromodulation for overactive
466 bladder with transcutaneous electrical nerve stimulation in adults – a randomized clinical
467 study. *Int J Pharm Bio Sci.* 2014;5(4):671-679.
- 468 21. Gungor Ugurlucan F, Onal M, Aslan E, Ayyildiz Erkan H, Kizilkaya Beji N, Yalcin
469 O. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in
470 the treatment of overactive bladder syndrome. *Gynecol Obstet Invest.* 2013;75(1):46-52.
471 doi:10.1159/000343756.
- 472 22. Vecchioli Scaldazza C, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M.
473 Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle
474 training for overactive bladder syndrome in women: results of a randomized controlled study.
475 *Int Braz J Urol.* 2017;43:121-126. doi:10.1590/S1677-5538.IBJU.2015.0719.
- 476 23. Martin-Garcia M, Crampton J. A single-blind, randomized controlled trial to evaluate
477 the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder
478 symptoms in women responders to percutaneous tibial nerve stimulation (PTNS). *Physiother*
479 *(United Kingdom).* 2018;105(4):469-475. doi:10.1016/j.physio.2018.12.002.
- 480 24. Ramírez-García I, Blanco-Ratto L, Kauffmann S, Carralero-Martínez A, Sánchez E.
481 Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous
482 stimulation in idiopathic overactive bladder syndrome: Randomized control trial. *Neurourol*
483 *Urodyn.* 2019;38(1):261-268. doi:10.1002/nau.23843.

- 484 25. Amarenco G, Ismael SS, Even-Schneider A, et al. Urodynamic Effect of Acute
485 Transcutaneous Posterior Tibial Nerve Stimulation in Overactive Bladder. *J Urol*.
486 2003;169(6):2210-2215. doi:10.1097/01.ju.0000067446.17576.bd.
- 487 26. Fernandez N, Chua ME, Ming JM, Zu'bi JMSF, Santos J, Lorenzo AJ, Braga LH,
488 Lopes RI. Neurostimulation Therapy for Nonneurogenic Overactive Bladder in Children: A
489 Meta-analysis. *Urol*. 2017, 110: 201–207. doi 10.1016/j.urology.2017.08.003.
- 490 27. Nüesch E, Trelle S, Reichenbach S, et al. The effects of excluding patients from the
491 analysis in randomised controlled trials: meta-epidemiological study. *BMJ*. 2009;339:b3244.
492 doi: 10.1136/bmj.b3244.
- 493 28. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and
494 inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res*
495 *Synth Methods*. 2012;3(2):98-110. doi:10.1002/jrsm.1044.
- 496 29. Lucas MG, Bedretidnova D, Bosch JLHR, et al. Guidelines on Urinary Incontinence.;
497 European Association of Urology, 2014. [https://uroweb.org/wp-content/uploads/20-Urinary-](https://uroweb.org/wp-content/uploads/20-Urinary-Incontinence_LR.pdf)
498 [Incontinence_LR.pdf](https://uroweb.org/wp-content/uploads/20-Urinary-Incontinence_LR.pdf)
- 499 30. Kamboonlert K, Panyasriwanit S, Tantisiriwat N, Kitisomprayoongkul W. Effects of
500 Bilateral Transcutaneous Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in
501 Spinal Cord Injury: A Urodynamic Study. *Arch Phys Med Rehabil* 102(6):1165-1169.
502 DOI:<https://doi.org/10.1016/j.apmr.2020.10.130>
503
504
505
506

507

508

509

510 Figure Legends

511 Figure 1. Flow-chart of study selection process in accordance with PRISMA guidelines.

512 Figure 2. Forest-plot of intra-vaginal versus tibial nerve electrical stimulation for urinary
513 symptoms (urinary frequency and nocturia).

514 Figure 3. Forest-plot of transcutaneous tibial nerve stimulation versus percutaneous tibial
515 nerve stimulation for urinary symptoms (urgency, urge incontinence, and urinary frequency).

516 Figure 4. Forest-plot of sacral versus tibial nerve stimulation for urinary symptoms (urinary
517 frequency and urge incontinence).

518 Figure 5. Forest plot comparing neurostimulation protocols for quality-of-life score.

519 Figure 6. Risk of bias

520

521

522

523

524